brexucabtagene autoleucel
gilead
['brexu-cel', 'zuma-2']
. collaborated in a 3-year follow-up to zuma-2 for r/r mcl. brexu-cel demonstrates durable responses with 49% in ongoing response 24 months post-infusion. there is potential for greater benefit if given earlier in course of disease. #ash2022 
John Theurer Cancer Center @HackensackUMC is among the nation's top cancer hospitals with 14 specialized divisions providing the most advanced care possible.